GenVec Eyes BLA Submission for Pancreatic Cancer Therapy In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears GenVec's Phase II/III trial for the gene-based oncologic TNFerade.
You may also be interested in...
GenVec Reports Positive Interim Survival Data For TNFerade In Pancreatic Cancer
Results presented at American Society of Clinical Oncology annual meeting show significant advantage in median survival versus standard care alone.
GenVec Reports Positive Interim Survival Data For TNFerade In Pancreatic Cancer
Results presented at American Society of Clinical Oncology annual meeting show significant advantage in median survival versus standard care alone.
GenVec TNFerade Potential Pulmonary Embolism Risk Prompts Clinical Hold
FDA initiates hold after three pulmonary embolisms, including one leading to death, are seen in highest dose studied in Phase II esophageal cancer trial. GenVec will provide additional data to FDA "over the next several days."